Friedlander, Terence W.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 869

A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 738

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 734

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 733

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Aggarwal, R., Starzinski, S., de Kouchkovsky, I., Koshkin, V., Bose, R., Chou, J., Desai, A., Kwon, D., Kaushal, S., Trihy, L., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 104

A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Shakhnazaryan, N., Curry, N., Rastogi, M., Avins, D., Pandey, S., de Kouchkovsky, I., Kwon, D., Desai, A., Fitzgerald, K. N., Bose, R., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 6

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0